Circulating tumor DNA as a biomarker in perihilar cholangiocarcinoma: a feasibility study

Completed

• Conditions: 10019815; biliary tract cancer; perihilar cholangiocarcinoma

• Registration Number: NL-OMON43203
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

-Patients older than 18 years
-Undergoing explorative laparotomy, diagnostic laparoscopy or percutaneous biopsy
-Able to understand the information given and provide written informed consent

Exclusion Criteria

-18 years or younger
-Unfit for laparotomy/ diagnostic laparoscopy/ biopsies or blood analyses in palliative
chemotherapy studies
-HIV/AIDS/hepatitis C in medical history
-Not able to give informed consent (language, intellectual capacities, etc.)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-To determine if ctDNA is presentcan be reliably detected in patients with PHC.<br /><br>-If ctDNA is presentdetected, we will assess if the mutational profile of the<br /><br>tumor matches the profile of the ctDNA</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-To perform a hotspot mutation analysis in patients with pathologically proven<br /><br>PHC</p><br>